Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$1.65
$0.05(3.50%)
At close: 4:00 PM EDT
$1.65
$0.05(3.50%)
Day’s Range― - ―
52-Week Range$1.25 - $3.54
Previous CloseN/A
Volume203.30K
Average Volume (3M)1.06M
Market Cap
$136.15M
Enterprise Value$92.08
Total Cash (Recent Filing)$112.31M
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding107,207,510
10 Day Avg. Volume1,207,223
30 Day Avg. Volume1,062,313
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.67Price Target Upside364.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$25.65M
Bulls Say, Bears Say
Bulls Say
Genome-edited Off-the-shelf PlatformThe CRISPR-based platform targets allogeneic, off-the-shelf cell therapies, which could improve manufacturing scalability and treatment availability if clinical efficacy is established. Engineering both T-cell and NK-cell approaches also provides multiple avenues for developing a differentiated oncology pipeline.
Manageable LeverageA relatively low debt burden provides more financial flexibility than highly leveraged peers and limits the immediate pressure from interest and refinancing obligations. Although losses have weakened equity and assets, manageable leverage can help preserve strategic options while clinical programs advance.
Clinical Development ProgressProgressing from encouraging Phase 1 CAR-T data toward a pivotal Phase 3 trial represents meaningful clinical advancement and could expand the company’s opportunity if later-stage results confirm benefit. This milestone supports pipeline validation and may improve partnership or funding prospects.
Bears Say
Persistent UnprofitabilityThe current revenue base is insufficient to cover operating costs, with negative gross profit and losses far exceeding revenue. Continued unprofitability limits internally generated funding, increases dependence on financing or partnerships, and makes future value highly dependent on successful clinical execution.
Sustained Cash BurnSubstantially negative operating and free cash flow indicate that the business consumes cash while advancing its programs rather than funding them internally. If losses persist, continued external funding may be required, creating dilution or financing constraints that could affect development pace and strategic flexibility.
Clinical Safety RiskSerious infections, cytopenias, and reported deaths create material safety uncertainty around the cell-therapy programs, even alongside encouraging response rates. Such risks can complicate later-stage trial execution, regulatory review, adoption, and the ability to translate early efficacy into a commercial product.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.25 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $136.15M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 11, 2027 which is in 175 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.084.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 107,207,510 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went down -1.863%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (364.65% Upside)
$7.67 (364.65% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$7.67
▲(364.65% Upside)
Technical Analysis
Ownership Overview
4.31% Insiders
5.38% Mutual Funds
10.07% Other Institutional Investors
68.26% Public Companies and
Individual Investors